Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease
Authors:
Open Access
- 29 September 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 2 (4) , otaa074
Abstract
Background: Nonadherence to biologic therapy in inflammatory bowel disease (IBD) is associated with risk of relapse, immunogenicity, and disease complications. Significant nonadherence prevalence is reported with tumor necrosis factor (TNF) antagonists but the risk of nonadherence with newer biologics with better safety profiles is unknown. This study aimed to investigate if IBD patient-preferences favoring biologic discontinuation vary by biologic class and analyze factors associated with such preferences. Methods: A convenience sample of 200 adults with IBD on biologic therapy treated at an academic outpatient center was surveyed using a 22-point questionnaire. Patient-preference favoring treatment discontinuation between TNF-antagonist and non-TNF-antagonist biologics [vedolizumab (VDZ)/ustekinumab (UST)] was compared using χ 2 test. Risk factors associated with a preference to discontinue biologic therapy were evaluated using univariable and multivariable logistic regression, and Spearman rank correlation analyses. Results: A total of 190 questionnaires were analyzed that contained data on preferences regarding biologic discontinuation (median age 36 years, 62% were females; 63% had Crohn disease; 56% were receiving a TNF antagonist, 31% VDZ, and 14% UST). Overall, 32% patients reported a preference to discontinue biologic treatment with a higher proportion among those receiving a TNF antagonist compared with VDZ/UST (39.6% vs 21.4%; P < 0.01). Current VDZ/UST use was independently associated with a reduced odds of patient-preference favoring biologic discontinuation [adjusted odds ratio: 2.67 (1.42–5.01); P < 0.01]. The most concerning factor to patients was the perceived risk of side effects. Patients on VDZ/UST perceived their therapy to be safer than those receiving a TNF antagonist (r = 0.2, P = 0.04). Conclusions: Patient-preference favoring treatment discontinuation is improved with VDZ/UST compared with TNF-antagonist biologic therapy.Keywords
This publication has 40 references indexed in Scilit:
- Adherence to Anti-TNF Therapy in Inflammatory Bowel DiseasesInflammatory Bowel Diseases, 2013
- Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ RegistryAmerican Journal of Gastroenterology, 2012
- Socioeconomic and psychological factors associated with nonadherence to treatment in inflammatory bowel disease patientsInflammatory Bowel Diseases, 2011
- Disease-Specific Knowledge, Coping, and Adherence in Patients with Inflammatory Bowel DiseaseDigestive Diseases and Sciences, 2011
- Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn’s disease patientsAdvances in Therapy, 2009
- Patient trust-in-physician and race are predictors of adherence to medical management in inflammatory bowel diseaseInflammatory Bowel Diseases, 2009
- Risk factors for non‐adherence to medication in inflammatory bowel disease patientsAlimentary Pharmacology & Therapeutics, 2007
- Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitisInflammatory Bowel Diseases, 2007
- The Common-Sense Model of self-regulation of health and illness: how can we use it to understand and respond to our patients' needs?Rheumatology, 2007
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005